From heart disease to neurodegeneration, Novartis makes bold deals in 2025 to expand its drug pipeline globally.
With Eli Lilly's recent acquisition of Verve Therapeutics and its PCSK9 candidate, delve into what the target represents.
The 2025 edition of the European Society for Medical Oncology(ESMO) was held this week in Berlin, delve into its key ...
Discover eight key AI biotech deals that have been made so far in 2025, spotlighting where industry leaders are betting big.
The global biotech industry is booming, and by 2025 it will reach an estimated market worth of $729B. But while great innovation is driven by emerging biotechs, these companies often lack resources, ...
The now-annual BIOSPAIN partnering conference took place in Barcelona this week. The event attracted the biggest players in the Iberian peninsula’s biotechnology industry and an increasing number of ...
As artificial intelligence (AI) becomes ever more integrated into the world of biotechnology, one of its latest applications is the discovery and design of peptides. This is a rapidly emerging field ...
As well as being known for its historical beauty and academic excellence, Cambridge has a reputation as a leading biotech hub, forming part of the U.K.’s “Golden Triangle” with Oxford and London. This ...
Asabys Partners, a Spanish venture capital (VC) firm focused on healthcare, has rolled Aliath Bioventures (formerly Alta Life Sciences) into its platform in a move that boosts its assets under ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results